<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02195089</url>
  </required_header>
  <id_info>
    <org_study_id>UMT2013-BLS-ILB-E710c</org_study_id>
    <secondary_id>12591</secondary_id>
    <nct_id>NCT02195089</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of BLS_ILB_E710c for the Fertile Women With Cervical Intraepithelial Neoplasia(CIN3)</brief_title>
  <official_title>A Phase 1/2a Trial to Evaluate the Efficacy and the Safety of BLS_ILB_E710c for the Fertile Women With Cervical Intraepithelial Neoplasia(CIN3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioLeaders Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioLeaders Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and the safety of BLS-ILB-E710c for
      the the fertile women with Cervical Intraepithelial Neoplasia (CIN3).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is to see the regression rate of Cervical Intraepithelial Neoplasia (CIN3) and to
      see the inducement of Cytotoxic T Lymphocyte.

      The First treatment group will be administered with BLS-ILB-E710c 500mg for 8 weeks followed
      by 1 week observation The Second treatment group will be administered with BLS-ILB-E710c
      1000mg for 8 weeks followed by 1 week observation The Third treatment group will be
      administered with BLS-ILB-E710c 1500mg for 8 weeks followed by 1 week observation The fourth
      treatment group will be administered with BLS-ILB-E710c Optimum dose for 8 weeks followed by
      8 weeks observation
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1 : Safety</measure>
    <time_frame>up to 9 weeks</time_frame>
    <description>Dose Limiting Toxicity(DLT) is assessed by NCI-CTC version 4.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2a : Regression rate</measure>
    <time_frame>screening and 9 weeks(option), 16 weeks.</time_frame>
    <description>Regression rate will be assessed at the time of screening and 9 weeks(option), 16 weeks. Regression means the change from the stage of CIN1 to normal</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reid Colposcopic Index</measure>
    <time_frame>Phase 1 : up to 9 weeks</time_frame>
    <description>Reid Colposcopic Index will be assessed at the time of screening,4 weeks 9.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reid Colposcopic Index</measure>
    <time_frame>Phase 2a : up to 16 weeks</time_frame>
    <description>Reid Colposcopic Index will be assessed at the time of screening,4 weeks, 9 weeks, 12 weeks, 16 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum anti-E7 antibody</measure>
    <time_frame>1 week, 9 weeks, 16 weeks</time_frame>
    <description>Serum anti-E7 antibody will be assessed at the time of 1 week, 9 weeks, 16 weeks.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Cervical Intraepithelial Neoplasia</condition>
  <arm_group>
    <arm_group_label>BLS_ILB_E710c 500mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: BLS_ILB_E710c 500mg
Dosage and duration: 2 capsules per day for 20 days (week 1,2,4 &amp; 8)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BLS_ILS_E710c 1000mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: BLS_ILS_E710c 1000mg
Dosage and duration: 4 capsules per day for 20 days (week 1,2,4 &amp; 8)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BLS_ILS_E710c 1500mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: BLS_ILS_E710c 1500mg
Dosage and duration: 6 capsules per day for 20 days (week 1,2,4 &amp; 8)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BLS_ILS_E710c 500mg</intervention_name>
    <description>- 2 capsules per day for 20 days (week 1,2,4 &amp; 8)</description>
    <arm_group_label>BLS_ILB_E710c 500mg</arm_group_label>
    <other_name>CIN3 Theraputic Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BLS_ILB_710c 1000mg</intervention_name>
    <description>- 4 capsules per day for 20 days (week 1,2,4 &amp; 8)</description>
    <arm_group_label>BLS_ILS_E710c 1000mg</arm_group_label>
    <other_name>CIN3 Theraputic Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BLS_ILS_E710c 1500mg</intervention_name>
    <description>- 6 capsules per day for 8 weeks (week 1,2,4 &amp; 8)</description>
    <arm_group_label>BLS_ILS_E710c 1500mg</arm_group_label>
    <other_name>CIN3 Theraputic Vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pre-menopausal patients between age of 20 and 50.

          -  Patients with cervical intraepithelial neoplasia 3(CIN3).

          -  Only infection with HPV type 16.

          -  Patients with Capable of observation of all of lesions by Colposcopy biopsy.

          -  Be informed of the nature of the study and will give written informed consent.

          -  Be agree with contraception during study

          -  White Blood Cell Count(WBC) over 4thous/ul, Hemoglobin above over 9.0g/dL Platelet
             over 150thous/uL and ANC(Absolute Neutrophil Count) over 1,500 /mm^3

          -  Normal for EKG(Electrocardiography)

          -  AST/ALT : 2.5 times less than normal range

        Exclusion Criteria:

          -  Autoimmune Disease or Prohibited drug(Therapy) bring about immunosuppressive.

          -  Patient that has medical history of hypersensitivity about Food containing Lactic acid
             bacteria or Lactic acid bacteria medication.

          -  Patient with Acute illness(ex. Acute Appendicitis, Myocardial infarction, Hemorrhage,
             meningitis etc.)

          -  Investigational product within three months before the start of the drug
             administration to patients treated with other test drug.

          -  Patient with Chronic pancreatitis currently or Patients diagnosed with acute
             pancreatitis.

          -  Organopathy Patient with Inflammatory intestineÂ·bowel disease, gastrointestinal
             tumors, ulcers, bleeding, perforation etc.

          -  Pregnant or lactating women

          -  Patient with HBV or HCV infection (except for Asymptomatic)

          -  Patient that Investigator judge

          -  Deemed inappropriate for researchers to judge the patient
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae-Kwan Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Guro Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tae Jin Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kwandong University College of Medicine Cheil Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jong Sup Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University, Korea Seoul St Mary's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chi-Heum Cho, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Dongsan Medical Center of Keimyung University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jong Hyeok Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Dongsan Medical Center of Keimyung University</name>
      <address>
        <city>Daegu</city>
        <zip>700-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kwandong University College of Medicine Cheil Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>100-380</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University, Korea Seoul St Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>152-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2014</study_first_submitted>
  <study_first_submitted_qc>July 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2014</study_first_posted>
  <last_update_submitted>April 18, 2016</last_update_submitted>
  <last_update_submitted_qc>April 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment of Cervical Intraepithelial Neoplasia(CIN3)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

